Neuronal vulnerability in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Double, Kay L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Copper; Iron; Neurodegeneration; Neuromelanin; Oxidative stress; Parkinson's disease; Vulnerability

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; CATECHOLAMINE; COPPER; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FERRITIN; LACTOFERRIN; NEUROMELANIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL GIRK 2; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; IRON;

ARTICLE; BRAIN REGION; COPPER DEFICIENCY; DOPAMINERGIC NERVE CELL; HUMAN; LEWY BODY; LIFESPAN; LOCUS CERULEUS; MELANOGENESIS; NERVE CELL DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PIGMENTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA PARS COMPACTA; BRAIN FUNCTION; BRAIN MATURATION; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPROTECTION;

EID: 84858690615     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70018-9     Document Type: Article

References (20)

1. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211.
2. Lim S, Fox S, Lang A. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009;66:167-72.
3. Double KL, Reyes S, Werry EL, Halliday GM. Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions? Prog Neurobiol 2010;92:316-29.
4. Marsden CD. Pigmentation in the nucleus substantia nigre of mammals. J Anat 1961;95:256-61.
5. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005;75:109-24.
6. Fedorow H, Halliday G, Rickert CH, Gerlach M, Riederer P, Double KL. Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging 2006;27:506-12.
7. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, et al. a-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128:2654-664.
8. Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, et al. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 2005;95:599-608.
9. Bohic S, Murphy K, Paulus W, Cloetens P, Salomé M, Susini J, et al. Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal Chem 2008;80:9557-66.
10. Kastner A, Hirsch, E, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992;59:1080-9.
11. Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies. J Neural Transm 2006;113: 769-74.
12. Gründemann J, Schlaudraff F, Liss L. UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains. Methods Mol Biol 2011;755:363-74.
13. Sian-Hülsmann J, Mandel S, Youdim MB. Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011;118:939-57.
14. Shamoto-Nagai M, Maruyama W, Yi H, Akao Y, Tribl F, Gerlach M, et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm 2006;113:633-44.
15. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, et al. Individual dopaminergic neurons show raised iron levels in Parkinson's disease. Neurology 2007;68:1820-25.
16. Orr C, Rowe D, Halliday G. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002;68:325-40.
17. He Y, Thong PS, Lee T, Leong SK, Mao BY, Dong F, et al. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 2003; 35:540-7.
18. Friedman A, Galazka-Friedman J, Koziorowski D. Iron as a cause of Parkinson disease -a myth or a well established hypothesis? Parkinsonism Relat Disord 2009;15:S212-4.
19. Bohic S, Carmona A, Ortega R, Reyes S, Carew-Jones F, Double KL. Metallomics of neuromelanin in Parkinsonian syndromes. Parkinsonism Relat Disord 2009; 15:S161-2.
20. Whitton PS. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease. Curr Opin Investig Drugs 2010;11:788-94.